Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorANSALONI, Matthieu
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPARIENTE, Antoine
IDREF: 13395711X
hal.structure.identifierCentre Émile Durkheim [CED]
dc.contributor.authorSMITH, Andy
dc.date.accessioned2021-04-23T09:20:49Z
dc.date.available2021-04-23T09:20:49Z
dc.date.issued2018
dc.identifier.issn1946-0171en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/27071
dc.description.abstractEnAs in many countries, in France, drug authorization is supposedly carried out by ‘independent’ agencies using ‘evidence-based medicine’. French Health Ministers, however, have recently destabilized this system by intervening directly to remove specific drugs from the market. Drawing upon a study of one such decision concerning antidiabetics, this article refutes an explanation of ministerial intervention in terms of the ‘heroic action’ of politicians. Instead, drawing on concepts from sociology and policy analysis, a generalizable analytical framework is proposed to capture deep shifts in power relations between representatives of four ‘fields’ (medical science, administration, party politics and journalism) which underlie ministerial intervention of this type. Specifically, the claim tested is that power struggles within and between those fields strongly structure actor behavior, but also create contingency. Indeed, in the case studied, these struggles coincided in such a way as to prompt and legitimate ministerial coercion. Rather than perpetuate the illusion of agency independence, social science should therefore shed light upon the intra and inter-field frictions which inevitably occur around the authorization of drugs.
dc.language.isoENen_US
dc.subject.enDrug agencies
dc.subject.enField theory
dc.subject.enIndependence
dc.subject.enEvidence-based policy
dc.title.enPower shifts in the regulation of medicines: an inter-field analysis of a French agency
dc.typeArticle de revueen_US
dc.identifier.doi10.1080/19460171.2017.1314220en_US
dc.subject.halSciences de l'Homme et Société/Science politiqueen_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
bordeaux.journalCritical Policy Studiesen_US
bordeaux.page314-334en_US
bordeaux.volume12en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue3en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionSciences Po Bordeaux
bordeaux.institutionCNRS
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcehal
hal.identifierhalshs-01719491
hal.version1
hal.exportfalse
workflow.import.sourcehal
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Critical%20Policy%20Studies&rft.date=2018&rft.volume=12&rft.issue=3&rft.spage=314-334&rft.epage=314-334&rft.eissn=1946-0171&rft.issn=1946-0171&rft.au=ANSALONI,%20Matthieu&PARIENTE,%20Antoine&SMITH,%20Andy&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée